DURECT (DRRX) to Release Earnings on Tuesday

Key Points

• DURECT Corporation (NASDAQ: DRRX) is set to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of $0.13 per share and revenue of $0.32 million.
• The stock recently traded down by 0.5%, closing at $1.85, and has a market cap of approximately $57.43 million.
• Analysts at Wall Street Zen initiated coverage with a "sell" rating, while Northland Capital Markets downgraded DURECT from "strong-buy" to "hold".

DURECT (NASDAQ:DRRX - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $0.32 million for the quarter.

DURECT Stock Up 0.5%

Shares of DRRX opened at $1.86 on Thursday. DURECT has a 52 week low of $0.48 and a 52 week high of $2.64. The company has a market capitalization of $57.73 million, a price-to-earnings ratio of -12.40 and a beta of 0.83. The stock's 50-day moving average price is $0.78 and its 200-day moving average price is $0.75.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DRRX. Wall Street Zen began coverage on shares of DURECT in a research note on Thursday, May 22nd. They issued a "sell" rating on the stock. Northland Capmk downgraded DURECT from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 29th.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.